Invention Grant
- Patent Title: 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
-
Application No.: US17130704Application Date: 2020-12-22
-
Publication No.: US11730721B2Publication Date: 2023-08-22
- Inventor: Xiaozhang Zheng , Pui Yee Ng , Mary-Margaret Zablocki
- Applicant: Valo Health, Inc.
- Applicant Address: US MA Boston
- Assignee: Valo Health, Inc.
- Current Assignee: Valo Health, Inc.
- Current Assignee Address: US MA Boston
- Agency: Choate, Hall & Stewart LLP
- Agent Michael A. Shinall; Nicholas J. Pace
- The original application number of the division: US16719332 2019.12.18
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61K31/407 ; A61K31/438 ; C07D221/20 ; C07D401/06 ; C07D209/54 ; A61P25/14 ; A61P25/28 ; A61P35/00
Abstract:
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Public/Granted literature
- US20210186940A1 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS Public/Granted day:2021-06-24
Information query
